Influenza A vaccine intranasal - Altimmune

Drug Profile

Influenza A vaccine intranasal - Altimmune

Alternative Names: ADhVN1203/04.H5; Influenza A vaccine H5N1 - Altimmune; NasoVAX

Latest Information Update: 22 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vaxin
  • Developer Altimmune
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H5N1 subtype

Most Recent Events

  • 21 Aug 2017 Altimmune files an IND application with the US FDA in USA for Influenza A infection (Prevention)
  • 01 Aug 2017 Altimmune plans a phase II trial for Influenza (Prevention) in USA (NCT03232567)
  • 04 May 2017 Altimmune plans a phase II trial for Influenza A infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top